Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Market NimbleGen Custom Arrays: Jun 22, 2004

NEW YORK, June 22 (GenomeWeb News) -Affymetrix will commercialize NimbleGen's customized microarrays, NimbleGen said today.

 

Under the agreement, Affymetrix will offer its customers made-to-order versions of the NimbleExpress array for use on the Affymetrix GeneChip instrument systems. Customers will be required to place a minimum order of 10 arrays, and there will be a four-week lead time on orders, NimbleGen said.

 

The NimbleExpress array is made using a maskless photolithography, enabling greater flexibility in design than the photolithography masks on traditional Affymetrix arrays.

 

The arrays can interrogate up to 12,000 transcripts for gene expression experiments, and can also be used for genome tiling and other experiments, NimbleGen said.

 

NimbleGen is based in Madison, Wis.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.